<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Aptos;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
font-size:12.0pt;
font-family:"Aptos",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Aptos",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;
mso-ligatures:none;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1103917069;
mso-list-template-ids:-140187708;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1717656311;
mso-list-template-ids:-547592474;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72" style="word-wrap:break-word">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:11.0pt">I apologize I did not attached the 2020 – 2023 Fentanyl Pills Analysis Report. Again, this email is being sent on behalf of David King, Executive Directive, San Diego Imperial HIDTA.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">Thank you,<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<div>
<p class="MsoNormal"><span style="font-size:11.0pt;color:#242424">Marla Kingkade</span><o:p></o:p></p>
<p class="MsoNormal" style="background:white"><span style="font-size:11.0pt;color:#242424">San Diego County Substance Use and Overdose Prevention Taskforce</span><o:p></o:p></p>
<p class="MsoNormal" style="background:white"><span style="font-size:11.0pt;color:#242424">Center for Community Research</span><o:p></o:p></p>
<p class="MsoNormal" style="background:white"><span style="font-size:11.0pt;color:#242424">8885 Rio San Diego Drive, Suite 335</span><o:p></o:p></p>
<p class="MsoNormal" style="background:white"><span style="font-size:11.0pt;color:black">San Diego, California, 92108</span><o:p></o:p></p>
<p class="MsoNormal" style="background:white"><span style="font-size:11.0pt;color:#242424"> <img width="104" height="81" style="width:1.0833in;height:.8452in" id="_x0000_i1030" src="cid:image003.png@01DABE3A.86BA2E20"></span><o:p></o:p></p>
<p class="MsoNormal" style="background:white"><b><span style="font-size:11.0pt;color:#242424">Confidentiality Notice.
</span></b><span style="font-size:11.0pt;color:#242424">This email message, including any attachments, is only for the intended recipient(s). This email and any attachments may contain information that is confidential, legally privileged, or otherwise protected
or exempt from disclosure under applicable law. If you are not a named recipient, or if you are named but believe that you received this email in error, please notify the sender immdiately by telephone or return email and promptly delete this email and any
attachments and copies thereof from your system. Any copying, distribution, dissemination, disclosure, or taking of any action in reliance on the contents of this transmission, by someone other than the intended addressee or its authorized agent is strictly
unauthorized and prohibited. If you are not the intended recipient, any copying, distribution, dissemination, disclosure, or other use of this email and any attachments is unauthorized and prohibited. Your receipt of this message is not intended to waive any
applicable privilege or claim of confidentiality. Thank you for your cooperation.</span><span style="font-size:11.0pt"><o:p></o:p></span></p>
</div>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">I wanted to forward this seizure data from the HIDTA Drug Threat Analysis Group (DTAG)
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<div>
<p class="MsoNormal"><span style="font-family:"Times New Roman",serif;mso-ligatures:standardcontextual">Thank you for the continued support,<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Times New Roman",serif;mso-ligatures:standardcontextual"><o:p> </o:p></span></p>
<p class="MsoNormal" style="text-align:justify"><b><span style="font-family:"Times New Roman",serif;mso-ligatures:standardcontextual">David King, Executive Director
<o:p></o:p></span></b></p>
<p class="MsoNormal" style="text-align:justify"><span style="font-family:"Times New Roman",serif;mso-ligatures:standardcontextual">San Diego Imperial Valley HIDTA<o:p></o:p></span></p>
<p class="MsoNormal" style="text-align:justify"><span style="font-family:"Times New Roman",serif;mso-ligatures:standardcontextual">Cell: (858) 248-2252<o:p></o:p></span></p>
<p class="MsoNormal" style="text-align:justify"><span style="font-size:11.0pt;mso-ligatures:standardcontextual"><a href="mailto:david.king@sdi.hidta.org"><span style="font-size:12.0pt;font-family:"Times New Roman",serif">david.king@sdi.hidta.org</span></a></span><span style="font-family:"Times New Roman",serif;mso-ligatures:standardcontextual">
<o:p></o:p></span></p>
<p class="MsoNormal" style="text-align:justify"><span style="font-size:2.0pt;font-family:"Times New Roman",serif;mso-ligatures:standardcontextual"><o:p> </o:p></span></p>
<p class="MsoNormal" style="text-align:justify"><span style="font-size:2.0pt;font-family:"Times New Roman",serif;mso-ligatures:standardcontextual"><o:p> </o:p></span></p>
<p class="MsoNormal" style="text-align:justify"><span style="font-size:11.0pt"><img border="0" width="87" height="86" style="width:.9047in;height:.8988in" id="Picture_x0020_3" src="cid:image001.png@01DABB5A.4A8F0A70" alt="Logo
Description automatically generated"><img border="0" width="98" height="100" style="width:1.0178in;height:1.0416in" id="Picture_x0020_4" src="cid:image002.png@01DABB5A.4A8F0A70" alt="Logo
Description automatically generated"></span><span style="font-size:11.0pt;mso-ligatures:standardcontextual"><o:p></o:p></span></p>
</div>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<div>
<div style="border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0in 0in 0in">
<p class="MsoNormal"><b><span style="font-size:11.0pt;font-family:"Calibri",sans-serif">From:</span></b><span style="font-size:11.0pt;font-family:"Calibri",sans-serif"> Hamby, David <<a href="mailto:DHamby@achidta.org">DHamby@achidta.org</a>>
<br>
<b>Sent:</b> Monday, June 10, 2024 1:14 PM<br>
<b>To:</b> King, David <<a href="mailto:David.King@sdi.hidta.org">David.King@sdi.hidta.org</a>><br>
<b>Cc:</b> Partridge, Ralph <<a href="mailto:Ralph.Partridge@sdi.hidta.org">Ralph.Partridge@sdi.hidta.org</a>><br>
<b>Subject:</b> 2020-2023 Fentanyl Pill Analysis Report<o:p></o:p></span></p>
</div>
</div>
<p class="MsoNormal"><o:p> </o:p></p>
<table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse">
<tbody>
<tr>
<td width="638" valign="top" style="width:6.65in;border:solid windowtext 1.0pt;background:red;padding:0in 5.4pt 0in 5.4pt">
<p class="MsoNormal" style="mso-margin-top-alt:auto"><b><span style="color:white">CAUTION:</span></b><span style="color:white"> This email was received from an EXTERNAL source, use caution when clicking links or opening attachments. If you believe this to be
a malicious and/or phishing email, please send this email as an attachment to <a href="mailto:Cyber-Internal@sd-lecc.org">
Cyber-Internal@sd-lecc.org</a></span><o:p></o:p></p>
</td>
</tr>
</tbody>
</table>
<div class="MsoNormal" align="center" style="text-align:center">
<hr size="1" width="100%" align="center">
</div>
<div>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">Dear Director King,<o:p></o:p></span></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">I am pleased to share with you the latest report from the Drug Threat Analysis Group, focusing on the analysis of fentanyl pill seizures across various HIDTA AORs
from 2020 to 2023.<o:p></o:p></span></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">This report evaluates the trends in fentanyl pill seizures across the network of thirty-three HIDTAs in the United States, providing a detailed breakdown of changes
observed over the specified period.<o:p></o:p></span></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">Key findings from the report include:<o:p></o:p></span></p>
</div>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="color:black;margin-bottom:8.0pt;mso-list:l1 level1 lfo3">
<span style="font-size:11.0pt;font-family:"Calibri",sans-serif">Generally low to non-existent fentanyl pill seizures across most HIDTA AORs up to 2022.<o:p></o:p></span></li><li class="MsoNormal" style="color:black;margin-bottom:8.0pt;mso-list:l1 level1 lfo3">
<span style="font-size:11.0pt;font-family:"Calibri",sans-serif">A noticeable seizure increase in the first quarter of 2023, followed by a decrease in the later quarters.<o:p></o:p></span></li><li class="MsoNormal" style="color:black;margin-bottom:8.0pt;mso-list:l1 level1 lfo3">
<span style="font-size:11.0pt;font-family:"Calibri",sans-serif">Arizona was a significant outlier in 2023, with nearly twice the seizures of the next highest region.<o:p></o:p></span></li><li class="MsoNormal" style="color:black;margin-bottom:8.0pt;mso-list:l1 level1 lfo3">
<span style="font-size:11.0pt;font-family:"Calibri",sans-serif">Higher prevalence of fentanyl pill seizures in the western AORs.<o:p></o:p></span></li></ul>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">These insights are critical as they offer a comparative perspective that could enhance the strategies and responses of your HIDTA to the fentanyl pill issue. While
this report concludes with data from the fourth quarter of 2023, it will be updated following the consolidation of the second quarter data for 2024 in July.<o:p></o:p></span></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">Don't hesitate to contact me with any questions or additional comments.<o:p></o:p></span></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">Thank you for your continued support.<o:p></o:p></span></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">Best regards,<o:p></o:p></span></p>
</div>
<div id="Signature">
<p><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">J. David Hamby </span><span style="font-family:"Calibri",sans-serif"><o:p></o:p></span></p>
<p><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">National Coordinator</span><span style="font-family:"Calibri",sans-serif"><o:p></o:p></span></p>
<p><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">Drug Threat Analysis Group (DTAG) </span><span style="font-family:"Calibri",sans-serif"><o:p></o:p></span></p>
<p><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">National Strategic Analysis Initiative (NSAI)</span><span style="font-family:"Calibri",sans-serif"><o:p></o:p></span></p>
<p><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">High Intensity Drug Trafficking Areas (HIDTA)</span><span style="font-family:"Calibri",sans-serif"><o:p></o:p></span></p>
<p><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:black">(423) 344-1422 </span><span style="font-family:"Calibri",sans-serif"><o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</div>
</div>
</body>
</html>